← Back to headlines
NeoGenomics Projects 2026 Revenue After PanTracer Liquid MolDX Approval
NeoGenomics has announced a revenue outlook of $797 million to $803 million for 2026, following the MolDX approval of its PanTracer Liquid product.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
